Zydus Company Profile
What is the competitive landscape for ZYDUS
ZYDUS has four hundred and eighteen approved drugs.
There is one US patent protecting ZYDUS drugs. There are twenty-seven tentative approvals on ZYDUS drugs.
Summary for Zydus
| US Patents: | 1 |
| Tradenames: | 335 |
| Ingredients: | 325 |
| NDAs: | 418 |
| Patent Litigation for Zydus: | See patent lawsuits for Zydus |
Drugs and US Patents for Zydus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | empagliflozin; metformin hydrochloride | TABLET;ORAL | 212198-001 | Jul 7, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Pharms Usa Inc | PROPRANOLOL HYDROCHLORIDE | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 090321-003 | Mar 25, 2011 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Pharms | BREXPIPRAZOLE | brexpiprazole | TABLET;ORAL | 213660-002 | Jan 10, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Pharms Usa Inc | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | INJECTABLE;INJECTION | 091534-001 | Feb 22, 2013 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Zydus Pharms | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206534-003 | Aug 8, 2017 | AB3 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for Zydus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015128877 | ⤷ Start Trial |
| Philippines | 12016501686 | ⤷ Start Trial |
| South Africa | 201606075 | ⤷ Start Trial |
| India | 651MU2014 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zydus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | 2015/053 | Ireland | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 2139494 | PA2020522 | Lithuania | ⤷ Start Trial | PRODUCT NAME: SASAGLIPTINAS IR DAPAGLIFLOZINAS; REGISTRATION NO/DATE: EU/1/16/1108 20160715 |
| 1452524 | 1690009-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114 |
| 2139494 | 2020C/533 | Belgium | ⤷ Start Trial | PRODUCT NAME: QTERN -SAXAGLIPTINE ET DAPAGLIFLOZINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1108 20160719 |
| 0193926 | 98C0038 | Belgium | ⤷ Start Trial | PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
